Section Arrow
RLYB.NASDAQ
- Rallybio Corporation
Quotes are at least 15-min delayed:2026/10/18 21:42 EDT
Regular Hours
Last
 16.28
-0.495 (-2.95%)
Day High 
16.695 
Prev. Close
16.775 
1-M High
17.24 
Volume 
37.14K 
Bid
16.25
Ask
17.49
Day Low
16.2 
Open
16.695 
1-M Low
16.55 
Market Cap 
89.12M 
Currency 美元 
P/E 2.1 
%Yield -- 
10-SMA 16.92 
20-SMA 16.93 
50-SMA 16.84 
52-W High 17.5738 
52-W Low 3.6701 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
7.99/-0.97
Enterprise Value
89.20M
Balance Sheet
Book Value Per Share
17.79
Cash Flow
Cash Flow Yield
0.28
Income Statement
Total Revenue
858.00K
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RXRXRecursion Pharmaceuticals3.465-0.695-16.71%-- 
TCRTAlaunos Therapeutics Inc.2.63+0.45+20.64%-- 
IBRXImmunityBio9.18-0.82-8.20%-- 
MRNAModerna218.01-18.49-7.82%-- 
SLSSELLAS Life Sciences Group9.98-1.36-11.99%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operationsas a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.